Altered intestinal tight junctions' expression in patients with liver cirrhosis: A pathogenetic mechanism of intestinal hyperpermeability

European Journal of Clinical Investigation

Volumn 42, Issue 4, 2012, Pages 439-446

  Assimakopoulos, Stelios F ^a   Tsamandas, Athanassios C ^a   Tsiaoussis, Georgios I ^a   Karatza, Elli ^a   Triantos, Christos ^a   Vagianos, Constantine E ^b   Spiliopoulou, Iris ^a   Kaltezioti, Valeria ^c   Charonis, Aristidis ^c   Nikolopoulou, Vassiliki N ^a   Scopa, Chrisoula D ^a   Thomopoulos, Konstantinos C ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b GENERAL HOSPITAL OF NIKEA   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Cirrhosis; Claudin 1; Intestinal permeability; Occludin; Tight junctions

Indexed keywords

CLAUDIN 1; ENDOTOXIN; OCCLUDIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DUODENUM BIOPSY; ENDOTOXEMIA; ESOPHAGUS VARICES; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE; INTESTINE CELL; INTESTINE EPITHELIUM; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; INTESTINE VILLUS; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TIGHT JUNCTION;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENTEROCYTES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; LIVER CIRRHOSIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PERMEABILITY; SEVERITY OF ILLNESS INDEX; TIGHT JUNCTIONS;

EID: 84858282462     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02609.x     Document Type: Article

References (38)

1. Ramos AR, Matte U, Goldani HA, Oliveira OL, Vieira SM, Silveira TR. Intestinal permeability assessed by 51Cr-EDTA in rats with CCl4 - induced cirrhosis. Arq Gastroenterol 2010;47:188-92.
2. Scarpellini E, Valenza V, Gabrielli M, Lauritano EC, Perotti G, Merra G et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol 2010;105:323-7.
3. Lee S, Son SC, Han MJ, Kim WJ, Kim SH, Kim HR et al. Increased intestinal macromolecular permeability and urine nitrite excretion associated with liver cirrhosis with ascites. World J Gastroenterol 2008;14:3884-90.
4. Aldersley MA, Howdle PD. Intestinal permeability and liver disease. Eur J Gastroenterol Hepatol 1999;11:401-3.
5. Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 2005;17:27-31.
6. Venkat D, Venkat KK. Hepatorenal syndrome. South Med J 2010;103:654-61.
7. Yi HM, Wang GS, Cai CJ, Yang Y, Lu MQ, Hu B et al. [Significance of lipopolysaccharides, toll-like receptor and inducible nitric oxide synthase in hepatopulmonary syndrome]. Zhonghua Yi Xue Za Zhi 2009;89:1521-4.
8. Senzolo M, Fries W, Buda A, Pizzuti D, Nadal E, Sturniolo GC et al. Oral propranolol decreases intestinal permeability in patients with cirrhosis: another protective mechanism against bleeding? Am J Gastroenterol 2009;104:3115-6.
9. Cariello R, Federico A, Sapone A, Tuccillo C, Scialdone VR, Tiso A et al. Intestinal permeability in patients with chronic liver diseases: its relationship with the aetiology and the entity of liver damage. Dig Liver Dis 2010;42:200-4.
10. Thalheimer U, De Iorio F, Capra F, del Mar Lleo M, Zuliani V, Ghidini V et al. Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study. Eur J Gastroenterol Hepatol 2010;22:1228-34.
11. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut 2006;55:1512-20.
12. Hollander D. Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep 1999;1:410-6.
13. Anderson JM, Van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am J Physiol 1995;269:G467-75.
14. Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2010;52:1829-35.
15. Spahr L, Bresson-Hadni S, Amann P, Kern I, Golaz O, Frossard JL et al. Allopurinol, oxidative stress and intestinal permeability in patients with cirrhosis: an open-label pilot study. Liver Int 2007;27:54-60.
16. Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology 2002;35:622-9.
17. Shu JC, Li QY, Yang QH, Zhang WR, Li ME, Zhang XY et al. [Ultrastructural changes of duodenal mucosas and their significance in patients with liver cirrhosis]. Zhonghua Gan Zang Bing Za Zhi 2007;15:254-7.
18. Natarajan SK, Ramamoorthy P, Thomas S, Basivireddy J, Kang G, Ramachandran A et al. Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: changes in glycosylation and luminal bacteria. Hepatology 2006;43:837-46.
19. Assimakopoulos SF, Scopa CD, Charonis A, Spiliopoulou I, Georgiou C, Nikolopoulou V et al. Experimental obstructive jaundice disrupts intestinal mucosal barrier by altering occludin expression: beneficial effect of bombesin and neurotensin. J Am Coll Surg 2004;198:748-57.
20. Markov AG, Veshnyakova A, Fromm M, Amasheh M, Amasheh S. Segmental expression of claudin proteins correlates with tight junction barrier properties in rat intestine. J Comp Physiol B 2010;180:591-8.
21. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422-33.
22. Assimakopoulos SF, Tsamandas AC, Louvros E, Vagianos CE, Nikolopoulou VN, Thomopoulos KC et al. Intestinal epithelial cell proliferation, apoptosis and expression of tight junction proteins in patients with obstructive jaundice. Eur J Clin Invest 2011;41:117-25.
23. Furuse M, Sasaki H, Tsukita S. Manner of interaction of heterogeneous claudin species within and between tight junction strands. J Cell Biol 1999;147:891-903.
24. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol 2001;159:2001-9.
25. Sun YJ, Chen WM, Zhang TZ, Cao HJ, Zhou J. Effects of cardiopulmonary bypass on tight junction protein expressions in intestinal mucosa of rats. World J Gastroenterol 2008;14:5868-75.
26. Sun X, Yang H, Nose K, Nose S, Haxhija EQ, Koga H et al. Decline in intestinal mucosal IL-10 expression and decreased intestinal barrier function in a mouse model of total parenteral nutrition. Am J Physiol Gastrointest Liver Physiol 2008;294:G139-47.
27. Simonovic I, Rosenberg J, Koutsouris A, Hecht G. Enteropathogenic Escherichia coli dephosphorylates and dissociates occludin from intestinal epithelial tight junctions. Cell Microbiol 2000;2:305-15.
28. McCall IC, Betanzos A, Weber DA, Nava P, Miller GW, Parkos CA. Effects of phenol on barrier function of a human intestinal epithelial cell line correlate with altered tight junction protein localization. Toxicol Appl Pharmacol 2009;241:61-70.
29. Parlesak A, Schafer C, Schutz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000;32:742-7.
30. Gulzar GM, Zargar SA, Jalal S, Alaie MS, Javid G, Suri PK et al. Correlation of hepatic venous pressure gradient with variceal bleeding, size of esophageal varices, etiology, ascites and degree of liver dysfunction in cirrhosis of liver. Indian J Gastroenterol 2009;28:59-61.
31. Rao RK, Basuroy S, Rao VU, Karnaky KJ Jr, Gupta A. Tyrosine phosphorylation and dissociation of occludin-ZO-1 and E-cadherin-beta-catenin complexes from the cytoskeleton by oxidative stress. Biochem J 2002;368:471-81.
32. Schmitz H, Fromm M, Bentzel CJ, Scholz P, Detjen K, Mankertz J et al. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci 1999;112(Pt 1):137-46.
33. Mankertz J, Tavalali S, Schmitz H, Mankertz A, Riecken EO, Fromm M et al. Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. J Cell Sci 2000;113(Pt 11):2085-90.
34. Marotta F, Chui DH, Jain S, Polimeni A, Koike K, Zhou L et al. Effect of a fermented nutraceutical on thioredoxin level and TNF-alpha signalling in cirrhotic patients. J Biol Regul Homeost Agents 2011;25:37-45.
35. Czeczot H, Scibior D, Skrzycki M, Podsiad M. Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. Acta Biochim Pol 2006;53:237-42.
36. Moustafa AH, Ali EM, Mohamed TM, Abdou HI. Oxidative stress and thyroid hormones in patients with liver diseases. Eur J Intern Med 2009;20:703-8.
37. Lee KC, Yang YY, Wang YW, Lee FY, Loong CC, Hou MC et al. Increased plasma malondialdehyde in patients with viral cirrhosis and its relationships to plasma nitric oxide, endotoxin, and portal pressure. Dig Dis Sci 2010;55:2077-85.
38. Natarajan SK, Thomas S, Ramamoorthy P, Basivireddy J, Pulimood AB, Ramachandran A et al. Oxidative stress in the development of liver cirrhosis: a comparison of two different experimental models. J Gastroenterol Hepatol 2006;21:947-57.